Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan;81(1):17-38.
doi: 10.1007/s00280-017-3501-8. Epub 2017 Dec 16.

Advances in ovarian cancer therapy

Alexander J Cortez  1 , Patrycja Tudrej  1 , Katarzyna A Kujawa  1 , Katarzyna M Lisowska  2
Affiliations
Review

Advances in ovarian cancer therapy

Alexander J Cortez et al. Cancer Chemother Pharmacol. 2018 Jan.

Abstract

Epithelial ovarian cancer is typically diagnosed at an advanced stage. Current state-of-the-art surgery and chemotherapy result in the high incidence of complete remissions; however, the recurrence rate is also high. For most patients, the disease eventually becomes a continuum of symptom-free periods and recurrence episodes. Different targeted treatment approaches and biological drugs, currently under development, bring the promise of turning ovarian cancer into a manageable chronic disease. In this review, we discuss the current standard in the therapy for ovarian cancer, major recent studies on the new variants of conventional therapies, and new therapeutic approaches, recently approved and/or in clinical trials. The latter include anti-angiogenic therapies, polyADP-ribose polymerase (PARP) inhibitors, inhibitors of growth factor signaling, or folate receptor inhibitors, as well as several immunotherapeutic approaches. We also discuss cost-effectiveness of some novel therapies and the issue of better selection of patients for personalized treatment.

Keywords: Biological drugs; Clinical trials; Ovarian cancer; Targeted therapy.

PubMed Disclaimer

References

    1. Kurman RJ, Shih IM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol. 2011;42(7):918–931. doi: 10.1016/j.humpath.2011.03.003. - DOI - PMC - PubMed
    1. Kujawa KA, Lisowska KM. Ovarian cancer—from biology to clinic. Postep Hig Med Dosw. 2015;69:1275–1290. doi: 10.5604/17322693.1184451. - DOI - PubMed
    1. Bignotti E, Tassi RA, Calza S, Ravaggi A, Bandiera E, Rossi E, Donzelli C, Pasinetti B, Pecorelli S, Santin AD. Gene expression profile of ovarian serous papillary carcinomas: identification of metastasis-associated genes. Am J Obstet Gynecol. 2007;196(3):245–246. doi: 10.1016/j.ajog.2006.10.874. - DOI - PubMed
    1. Lisowska KM, Olbryt M, Student S, Kujawa KA, Cortez AJ, Simek K, Dansonka-Mieszkowska A, Rzepecka IK, Tudrej P, Kupryjanczyk J. Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival. J Cancer Res Clin. 2016;142(6):1239–1252. doi: 10.1007/s00432-016-2147-y. - DOI - PMC - PubMed
    1. Lisowska KM, Olbryt M, Dudaladava V, Pamula-Pilat J, Kujawa K, Grzybowska E, Jarzab M, Student S, Rzepecka IK, Jarzab B, Kupryjanczyk J. Gene expression analysis in ovarian cancer—faults and hints from DNA microarray study. Front Oncol. 2014;4:6. doi: 10.3389/fonc.2014.00006. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances